Nice coverage in Pharma's Almanac of Aptuit's collaboration with Bioversys.
Aptuit in Bacteria Resistance Collaboration
Drug development firm Aptuit has begun a joint collaboration with the Swiss biotech Bioversys that is aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. The partners hope that this will make it possible to combat antibiotic resistance in the treatment of serious infections. The deal followed on from an agreement made by Aptuit with Massachusetts General Hospital (MGH) in the same field.
Read full article by Emilie Branch from the Pharma's Almanac site